OrbiMed’s Alimera Sciences ALIM Stock Holding History

OrbiMed’s Portfolio ALIM Stock Details ALIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-16,667	Closed	-$180K	–	144
2018 Q4	$180K	Hold	16,667	–	–	﹤0.01%	129
2018 Q3	$245K	Hold	16,667	–	–	﹤0.01%	149
2018 Q2	$245K	Hold	16,667	–	–	﹤0.01%	146
2018 Q1	$258K	Hold	16,667	–	–	﹤0.01%	140
2017 Q4	$333K	Hold	16,667	–	–	﹤0.01%	130
2017 Q3	$338K	Hold	16,667	–	–	﹤0.01%	140
2017 Q2	$348K	Hold	16,667	–	–	﹤0.01%	136
2017 Q1	$350K	Hold	16,667	–	–	﹤0.01%	134
2016 Q4	$270K	Hold	16,667	–	–	﹤0.01%	131
2016 Q3	$373K	Hold	16,667	–	–	﹤0.01%	139
2016 Q2	$308K	Sell	16,667 -83,333	-83%	-$2.22M	﹤0.01%	136
2016 Q1	$2.63M	Hold	100,000	–	–	0.03%	126
2015 Q4	$3.63M	Hold	100,000	–	–	0.03%	114
2015 Q3	$3.31M	Hold	100,000	–	–	0.03%	119
2015 Q2	$6.92M	Hold	100,000	–	–	0.06%	114
2015 Q1	$7.51M	Hold	100,000	–	–	0.06%	112
2014 Q4	$8.31M	Hold	100,000	–	–	0.08%	100
2014 Q3	$8.13M	Hold	100,000	–	–	0.08%	100
2014 Q2	$8.97M	Hold	100,000	–	–	0.11%	91
2014 Q1	$11.8M	Buy	+100,000	New	+$9.71M	0.15%	81

Other funds holding ALIM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

OrbiMed's ALIM Position: Q1 2019 in Review

OrbiMed sold out of Alimera Sciences (ALIM) in Q1 2019, closing a stake of 16,667 shares — an estimated $180K sold.

OrbiMed first reported a position in ALIM in Q1 2014 and held it in 20 quarters. The position peaked at $11.8M in Q1 2014. 39 funds tracked by Wall St. Rank hold ALIM as of Q1 2019.

OrbiMed reported no remaining Alimera Sciences position as of Q1 2019 after selling out during the quarter.
OrbiMed sold 16,667 Alimera Sciences shares in Q1 2019, an estimated $180K.
OrbiMed first reported a position in Alimera Sciences in Q1 2014 and held it in 20 quarters.
OrbiMed's Alimera Sciences position peaked at $11.8M in Q1 2014.
39 funds tracked by Wall St. Rank held Alimera Sciences as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.